Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $32.00 Price Target at Stifel Nicolaus

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective dropped by research analysts at Stifel Nicolaus from $36.00 to $32.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 159.32% from the stock’s previous close.

A number of other research firms have also recently commented on ZNTL. HC Wainwright restated a “buy” rating and set a $46.00 target price on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Wedbush upped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Zentalis Pharmaceuticals Price Performance

ZNTL traded up $0.03 on Wednesday, reaching $12.34. 154,808 shares of the stock were exchanged, compared to its average volume of 773,694. The company’s 50-day moving average price is $13.76 and its 200 day moving average price is $13.43. The firm has a market capitalization of $876.26 million, a PE ratio of -2.71 and a beta of 1.82. Zentalis Pharmaceuticals has a fifty-two week low of $9.56 and a fifty-two week high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same period in the prior year, the business posted ($1.07) earnings per share. As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Melissa B. Epperly sold 2,573 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the completion of the transaction, the chief financial officer now directly owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Eventide Asset Management LLC boosted its position in Zentalis Pharmaceuticals by 47.9% in the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after buying an additional 3,745,936 shares during the period. Decheng Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $31,809,000. Vanguard Group Inc. boosted its position in shares of Zentalis Pharmaceuticals by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after acquiring an additional 307,490 shares in the last quarter. Federated Hermes Inc. raised its position in shares of Zentalis Pharmaceuticals by 10.9% during the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock worth $32,733,000 after acquiring an additional 212,872 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its stake in Zentalis Pharmaceuticals by 79.4% in the fourth quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock valued at $5,456,000 after purchasing an additional 159,439 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.